Advertisement

Topics

Fujifilm Diosynth Opens Cambridge, MA, Collaboration Center

06:07 EDT 8 Jun 2018 | Genetic Engineering News

BOSTON—Fujifilm Diosynth Biotechnologies says the new collaboration center it opened in Cambridge, MA, is part of an ongoing effort to grow its contract development and manufacturing organization (CDMO) business to $1 billion in annual sales by March 2024. Fujifilm Diosynth, a CDMO focused on developing and manufacturing gene therapies and recombinant biopharmaceuticals, said the new Cambridge Collaboration Center is designed to help the company forge partnerships with the large concentration of academic researchers and biopharma businesses in the region anchored by Cambridge and neighboring Boston. “We want to connect with bioindustry in the gene therapy space because we don’t have all the answers. We think one of the things that we can bring is to be the meeting place for the biotech industry in Cambridge, specifically companies with a gene therapy bias,” Fujifilm Diosynth CEO Steve Bagshaw, CEng, FIChemE, told GEN in an interview Tuesday at the 2018 ...

Original Article: Fujifilm Diosynth Opens Cambridge, MA, Collaboration Center

NEXT ARTICLE

More From BioPortfolio on "Fujifilm Diosynth Opens Cambridge, MA, Collaboration Center"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...